← Back to Patent Explorer
US4241174A Expired / Lapsed US ⏱️ 0.0 years remaining

Interferon assay

Assignee: Roche Diagnostics Corp
•
Filing: 1978-11-24
•
Granted: 1980-12-23
•
Expires: 1998-11-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A rapid cytopathic effect inhibition assay for interferon is disclosed. The assay can be completed in about 16 hours or less, allowing its use to assist in clinical diagnosis of viral infections and also, in monitoring the production and purification of interferon whether leukocyte or fibroblast.

Inventors

  • 👤 Philip C. Familletti
  • 👤 Sidney Pestka
  • 👤 Sara Rubinstein

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-27 14:32
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; C; C12; C12Q; C12Q1/00; C12Q1/70; Y; Y10; Y10S; Y10S435/00; Y10S435/811

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 188 words
An improved assay for interferon comprising the following steps in combination: a. contacting a serially diluted and segregated interferon containing sample in the presence of a cell support medium with a viable cell line preparation in the form of a cell suspension, said cell line known to be sensitive to the interferon type to be assayed, so as to form an interferon-cell line mixture in the form of a suspension; b. allowing said interferon-cell line mixture to incubate from 0 to 1 hour; c. adding a challenge virus preparation to each of said segregated, serially diluted interferon-cell line mixtures and allowing the resulting mixtures to incubate from about 12 to 18 hours; d. providing a virus control mixture comprising said viable cell line preparation and said challenge virus preparation, and a cell control comprising said viable cell line preparation; e. reading said assay mixtures when the said virus control mixture shows 100% cytopathic effect, whereby the titer of interferon in said sample is determined as the reciprocal of the dilution of the mixture showing a 50% reduction in cytopathic effect as compared to the virus and cell controls.
Claim 2
Dependent Claim 188 words
An improved assay for interferon comprising the following steps in combination: a. contacting a serially diluted and segregated interferon containing sample in the presence of a cell support medium with a viable cell line preparation in the form of a cell suspension, said cell line known to be sensitive to the interferon type to be assayed, so as to form an interferon-cell line mixture in the form of a suspension; b. allowing said interferon-cell line mixture to incubate from 0 to 1 hour; c. adding a challenge virus preparation to each of said segregated, serially diluted interferon-cell line mixtures and allowing the resulting mixtures to incubate from about 12 to 18 hours; d. providing a virus control mixture comprising said viable cell line preparation and said challenge virus preparation, and a cell control comprising said viable cell line preparation; e. reading said assay mixtures when the said virus control mixture shows 100% cytopathic effect, whereby the titer of interferon in said sample is determined as the reciprocal of the dilution of the mixture showing a 50% reduction in cytopathic effect as compared to the virus and cell controls.
Claim 3
Dependent Claim 18 words
The assay of claim 1 wherein said interferon containing sample consists of human leukocyte or human fibroblast interferon.
Claim 4
Dependent Claim 22 words
The assay of claim 2 wherein said cell line consists of bovine kidney cells and said challenge virus is vesicular stomatitis virus.
Claim 5
Dependent Claim 16 words
The assay of claim 3 wherein said assay is read after staining of the cell preparations.
Claim 6
Dependent Claim 14 words
The assay of claim 4 wherein the dye-fixative solution is crystal violet in methanol.
Claim 7
Dependent Claim 20 words
The assay of claim 1 wherein the said incubation steps are carried out at a temperature of about 37° C.

References Cited (Backward Citations)

US3910824A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1983-12-23 1984-06-23 1984-12-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1987-12-23 1988-06-23 1988-12-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1991-12-23 1992-06-23 1992-12-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag